Harrow Health completes transfer of Triesence NDA

Harrow announced the completion of the transfer to Harrow of the new drug application, or NDA, for Triesence 40 mg/mL, a synthetic corticosteroid indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids as well as visualization during vitrectomy. In January of 2023, Harrow agreed to acquire the U.S. commercial rights to Triesence. Aside from the transfer of the TRIESENCE NDA ahead of the date previously agreed to, all other acquisition terms remain unchanged.